ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0900

Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro

Marina Barguil Macedo and Christian Lood, University of Washington, Seattle, WA

Meeting: ACR Convergence 2023

Keywords: complement, immunology, Mitochondrial Dysfunction, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0899–0933) SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Mitochondria are extruded upon cell death and platelet activation, being elevated in several inflammatory conditions, including systemic lupus erythematosus (SLE). Mitochondria are immunogenic, with SLE patients having anti-mitochondrial antibodies (AMA), including anti-cardiolipin antibodies, which are associated with thrombosis. However, the role of AMAs, as well as other opsonins such as complement, in regulating mitochondrial-mediated platelet activation, has not been carefully investigated. In the current study, we set out to determine the role of AMAs and complement components in modifying the ability of extracellular mitochondria to promote platelet activation.

Methods: Ultra-pure mitochondria were isolated from HepG2 cells through Dounce homogenization and differential centrifugation. Mitochondria were pre-opsonized with isolated IgG from SLE patients or healthy controls, as well as complement C3-deficient or sufficient plasma, prior to adding the washed opsonized mitochondria to platelets from healthy individuals. Markers of platelet activation were assessed by flow cytometry (P-Selectin; CD62P) or by ELISA of the supernatant (platelet factor 4; PF-4, and thrombospondin-1; TSP-1).

Results: Extracellular mitochondria were able to induce CD62P on the platelet surface (8x increase from baseline, p< 0.0001, Figure 1A), even to a higher extent than ADP, a known platelet activator, used as positive control. Surprisingly, opsonization of mitochondria with SLE IgG only marginally amplified platelet activation. Mitochondria supported complement activation, with binding of both C1q and activated C3 to the outer membrane. Importantly, C3-sufficient, but not deficient, sera supported enhanced mitochondrial-mediated platelet activation as determined by CD62P, PF-4 (3x increase from baseline, p< 0.001) and TSP-1 levels (4x increase from baseline, p< 0.001, Figure 1B). Of note, EDTA, a chelator of divalent cations, Ca2+ and Mg2+ necessary for complement activation, prevented mitochondrial opsonization with C3, and prevented subsequent platelet activation.

Conclusion: Extracellular mitochondria were able to induce CD62P on the platelet surface (8x increase from baseline, p< 0.0001, Figure 1A), even to a higher extent than ADP, a known platelet activator, used as positive control. Surprisingly, opsonization of mitochondria with SLE IgG only marginally amplified platelet activation. Mitochondria supported complement activation, with binding of both C1q and activated C3 to the outer membrane. Importantly, C3-sufficient, but not deficient, sera supported enhanced mitochondrial-mediated platelet activation as determined by CD62P, PF-4 (3x increase from baseline, p< 0.001) and TSP-1 levels (4x increase from baseline, p< 0.001, Figure 1B). Of note, EDTA, a chelator of divalent cations, Ca2+ and Mg2+ necessary for complement activation, prevented mitochondrial opsonization with C3, and prevented subsequent platelet activation.

Supporting image 1

Figure 1. Mitochondrial-mediated platelet activation. A) Platelet P-selectin (CD62P) expression upon co-culture with mitochondria (mito) or ADP. B) Platelet activation (TSP_1) upon co-culture with mitochondria pre-opsonized with C3-sufficient (purple diamond) or deficient (blue down-pointing triangle) sera in presence of absence of EDTA (pink open circle).


Disclosures: M. Barguil Macedo: None; C. Lood: Amytryx, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Citryll, 2, Eli Lilly, 5, Gilead, 5, Horizon Therapeutics, 5, Pfizer, 5, Redd Pharma, 5, 11.

To cite this abstract in AMA style:

Barguil Macedo M, Lood C. Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/complement-deposition-on-extracellular-mitochondria-induces-platelet-activation-in-vitro/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complement-deposition-on-extracellular-mitochondria-induces-platelet-activation-in-vitro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology